BRAF and dermatological toxicity: Combination strategies involving both MEK and BRAF inhibitors together with anti-EGFRs also significantly improved PFS in previously untreated melanoma patients.57 The combination of the BRAF inhibitor, dabrafenib, with panitumumab and the MEK inhibitor trametinib has also been tested with interesting results (ORR 26%, median PFS 4.1 months), with the limitation of significant skin toxicities.57 The combination of the BRAF inhibitor, dabrafenib, with panitumumab and the MEK inhibitor trametinib (ORR, 26%; median PFS, 4.1 months), with the limitation of significant skin toxicities.58